The cost of antiretroviral drugs and influence on prescribing policies

被引：8

作者：

Jones, Rachael ^{[1
]}

Gazzard, Brian ^{[1
]}

机构：

[1] Chelsea & Westminster Hosp, Dept HIV & GU Med, London SW10 9NH, England

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 2006年 / 17卷 / 08期

关键词：

cost; antiretroviral drugs; prescribing policy;

D O I：

10.1258/095646206778145587

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

With the advent of highly active antiretroviral therapy (HAART), the prognosis for HIV-infected individuals with access has been transformed. HAART provides one of the most cost-effective treatments for any chronic disease. Immediate cost remains a legitimate factor when chosing HAART regimens, however, the cost of long-term side-effects and adherence issues must also be considered. The review examines the cost issues associated with HAART prescription and its influence on prescribing policies.

引用

页码：499 / 506

页数：8

共 82 条

[61] Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection [J].

Palella, FJ ;

Delaney, KM ;

Moorman, AC ;

Loveless, MO ;

Fuhrer, J ;

Satten, GA ;

Aschman, DJ ;

Holmberg, SD .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (13) :853-860

[62] Reasons for early abacavir discontinuation in HIV-infected patients [J].

Peyriere, H ;

Guillemin, V ;

Lotthe, A ;

Baillat, V ;

Fabre, J ;

Favier, C .

ANNALS OF PHARMACOTHERAPY, 2003, 37 (10) :1392-1397

[63] Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy [J].

Pineda, JA ;

Macías, J .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (04) :417-419

[64]

POWDERLY W, 2004, 11 C RETR OPP INF 11

[65] Antiretroviral therapy in patients with hepatitis and HIV: Weighing risks and benefits [J].

Powderly, WG .

CLINICAL INFECTIOUS DISEASES, 2004, 38 :S109-S113

[66]

Pozniak A, 2003, HIV Med, V4 Suppl 1, P1

[67] Severe cutaneous reactions associated with the use of human immunodeficiency virus medications [J].

Rotunda, A ;

Hirsch, RJ ;

Scheinfeld, N ;

Weinberg, JM .

ACTA DERMATO-VENEREOLOGICA, 2003, 83 (01) :1-9

[68] Results of a phase 2 clinical trial at 48 weeks (AI424-007): A dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects [J].

Sanne, I ;

Piliero, P ;

Squires, K ;

Thiry, A ;

Schnittman, S .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2003, 32 (01) :18-29

[69] Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study [J].

Schooley, RT ;

Ruane, P ;

Myers, RA ;

Beall, G ;

Lampiris, H ;

Berger, D ;

Chen, SS ;

Miller, MD ;

Isaacson, E ;

Cheng, AK .

AIDS, 2002, 16 (09) :1257-1263

[70] Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients [J].

Scott, JD .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2005, 62 (08) :809-815

← 1 2 3 4 5 6 7 8 9 →